Vericel Grew 26% and Its Own Long-Range Plan Got Old
A blowout third quarter, a burn-care guidance framework that finally broke, and a stock that has spent ninety days going nowhere
VCEL · Earnings Call · 2026-11-05
The plan was written for a slower company
When Josh Jennings of TD Cowen opened the Q&A by asking whether Vericel's long-range plan now looks too easy, he was asking the only question that mattered. The company has spent years pointing at a $500 million revenue ambition with high-30s adjusted EBITDA margins by the end of the decade. With full-year 2026 guidance now at $344–346 million — the third consecutive quarterly raise, and $24 million above where the year started — that target requires roughly 13% annual growth from here. The company just did 26% in a quarter. Joe Mara did not retreat:He explicitly declined to re-base the targets. That is a notable non-event: a management team whose own guidance template has been outgrown, choosing to leave the old goalpost standing rather than raise it and reset expectations. Investors should read the omission, not the reiteration. The quarter itself: revenue $85.4 million, up 26%; MACI $67.4 million, up 21% and the sixth straight quarter of 20%+ growth; burn care $18 million, up 52%; gross margin above 73%; adjusted EBITDA $25.2 million, up 48%, at a 30% margin; GAAP net income $14.2 million. Note that the reported fundamentals supplied here still stop at the June quarter — $77 million of revenue, up 22%, is one quarter stale and already obsolete.I would say at this point, we are probably kind of outpacing our expectations to kind of hit those targets, particularly on a top-line level, where it is kind of getting that half billion by the end of the decade.
What actually changed is penetration, not price
The bull case for years rested on adding surgeons. That has quietly flipped. Asked how much growth comes from new surgeon engagement, Nick Colangelo gave the most important sentence on the call: “we are continuing to add new surgeons, but we're also seeing, again, more biopsies per surgeon.” — Nick Colangelo, President and Chief Executive Officer · 2026-11-05 Record third-quarter biopsies, implants and biopsying surgeons; biopsy growth accelerating each quarter of 2026; the strongest biopsy month since launch in October. The mechanism is MACI Arthro adoption: a record number of MACI Arthro procedures, the highest share of total MACI procedures since launch, and more than a quarter of sub-4cm condyle defects now treated arthroscopically. Management's tell is that once a surgeon clears a critical mass of Arthro cases, utilization rises across all defect types — the deeper penetration thesis showing up in the numbers rather than the slide deck. The keyword record confirms the rotation: commercial initiatives and surgeon engagement now head the company's own theme list, while sales force expansion — a top-five theme through 2025 and into February — has fallen out of the top thirty entirely. The hiring story is over; the leverage story has begun. This is also where Vericel brushes against a broader tape. The market's recent winners have been procedure-volume and site-of-migration stories — site of care and Ambulatory Surgery Center have both been strong 90-day movers globally, and Edwards Lifesciences' procedure growth language rhymes with it. Vericel never uses those words, but a less invasive, faster-recovery arthroscopic delivery is precisely that trade. It is riding the wave without claiming it.The framework that finally cracked
The quiet story is burn care. In July 2025, Mara announced a retreat:That run rate was ~$10 million a quarter, and it became the 2026 guide: $46–50 million. Three quarters later, Epicel printed a record $12.7 million and commercial NexoBrid a record $2.3 million, and full-year burn care guidance jumped to roughly $54 million. Ryan Zimmerman pressed exactly the right nerve — at what point does the run rate get re-based? Colangelo's answer was honest about the limits of control: “we can't control the number of catastrophic burns that occur or the number of patients that survive to be treated.” — Nick Colangelo, President and Chief Executive Officer · 2026-11-05 Mara added only that the framework "has worked quite well this year" and will be adjusted "as needed." So the beat is real but the guide stays deliberately low-anchored — a repeatable pattern worth discounting appropriately. Which brings us to the ritual. Every year Vericel starts conservative and beats. February 2026: “we just want a very, I would say, prudent and disciplined start of the year in our initial guide.” — Joseph Mara, Chief Financial Officer · 2026-02-26 November 2025, on 2026 MACI: “we're not going to get ahead of ourselves and plan to start the year guiding above the trends of that 20%.” — Joseph Mara, Chief Financial Officer · 2025-11-06 And now, on 2027, the same move in new clothing — “if you really look at where consensus is, that is probably a pretty good starting point” — Joe Mara, Chief Financial Officer · 2026-11-05 — with the explicit caveat that “we will start a little bit more conservatively than that.” — Joe Mara, Chief Financial Officer · 2026-11-05 The good starting point language is now three years old and always means the same thing: the internal internal expectation is above the number they give you. Note also that consensus has entered the company's own keyword vocabulary — management is now explicitly anchoring to the sell side rather than to its own model.we're essentially shifting to more of a run rate concept versus kind of thinking about our forecast and how we start the quarter.